John F. Harms

2.5k citations

32 papers · 1.6k indexed · h-index 20

Molecular Biology top 10%
Pharmacology top 2%
Oncology top 10%
Cellular and Molecular Neuroscience top 10%
Organic Chemistry top 10%

Co-authors: Danny R. Welch Christopher J. Schmidt Douglas S. Chapin Frank S. Menniti Sheryl A. McCarthy Judith A. Siuciak Lorraine A. Lebel Mary E. Miele
Topics: Phosphodiesterase function and regulation (10 papers)Receptor Mechanisms and Signaling (8 papers)Cholinesterase and Neurodegenerative Diseases (6 papers)
Cited by: Pharmacology Molecular Biology Cellular and Molecular Neuroscience
Journals: Journal of Neuroscience Biochemistry Cancer Research
Partner nations: United States Netherlands India

In The Last Decade

John F. Harms

32 papers receiving 1.6k citations

Peers

Countries citing papers authored by John F. Harms

Since Specialization

Citations

This map shows the geographic impact of John F. Harms's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John F. Harms with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John F. Harms more than expected).

Fields of papers citing papers by John F. Harms

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John F. Harms. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John F. Harms. The network helps show where John F. Harms may publish in the future.

Co-authorship network of co-authors of John F. Harms

This figure shows the co-authorship network connecting the top 25 collaborators of John F. Harms. A scholar is included among the top collaborators of John F. Harms based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John F. Harms. John F. Harms is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phosphodiesterase 9A in Brain Regulates cGMP Signaling Independent of Nitric-Oxide 2019 ·Frontiers in Neuroscience ·John F. Harms,Frank S. Menniti,Christopher J. Schmidt	21
2	Reversal of neurobehavioral social deficits in dystrophic mice using inhibitors of phosphodiesterases PDE5A and PDE9A 2016 ·Translational Psychiatry ·Matthew S. Alexander,Molly Gasperini,Peter T. Tsai,Devin Gibbs,Janelle M. Spinazzola,Jamie L. Marshall,Michael Feyder,Mathew T. Pletcher,Eugene L. Piatnitski Chekler,Carl Morris,Mustafa Şahin,John F. Harms,C J Schmidt,Robin J. Kleiman,Louis M. Kunkel	15
3	Facilitation of Corticostriatal Transmission following Pharmacological Inhibition of Striatal Phosphodiesterase 10A: Role of Nitric Oxide-Soluble Guanylyl Cyclase-cGMP Signaling Pathways 2015 ·Journal of Neuroscience ·Fernando E. Padovan‐Neto,Stephen Sammut,Shreaya Chakroborty,(unknown),Sarah Threlfell,(unknown),(unknown),John F. Harms,Christopher J. Schmidt,Anthony R. West	40
4	A single nucleotide polymorphism of the cholecystokinin-B receptor predicts risk for pancreatic cancer 2012 ·Cancer Biology & Therapy ·Jill P. Smith,John F. Harms,Gail L. Matters,Christopher O. McGovern,Francesca Ruggiero,Jiangang Liao,Kristin Fino,(unknown),(unknown),John A. Phillips	15
5	Discovery of a Novel Class of Phosphodiesterase 10A Inhibitors and Identification of Clinical Candidate 2-[4-(1-Methyl-4-pyridin-4-yl-1 H -pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the Treatment of Schizophrenia†Coordinates of the PDE10A crystal structures have been deposited in the Protein Data Bank for compound 1 (3HQW), 2 (3HQY), 3 (3HQW) and 9 (3HR1). 2009 ·Journal of Medicinal Chemistry ·Patrick R. Verhoest,Douglas S. Chapin,Michael L. Corman,Kari R. Fonseca,John F. Harms,Xinjun Hou,Eric S. Marr,Frank S. Menniti,Frederick Nelson,Rebecca E. O’Connor,Jayvardhan Pandit,(unknown),Anne W. Schmidt,Christopher J. Schmidt,(unknown),Spiros Liras	172
6	Growth of Human Pancreatic Cancer Is Inhibited by Down-Regulation of Gastrin Gene Expression 2009 ·Pancreas ·Gail L. Matters,John F. Harms,Christopher O. McGovern,Calpurnia Jayakumar,(unknown),Zachary P. Smith,Melissa C. Nelson,(unknown),(unknown),James M. Kaiser,Mark Kester,Jill P. Smith	28
7	Vagotomy enhances experimental metastases of 4THMpc breast cancer cells and alters Substance P level 2008 ·Regulatory Peptides ·Nuray Erin,Güliz A. Barkan,John F. Harms,Gary A. Clawson	63
8	The Opioid Antagonist Naltrexone Improves Murine Inflammatory Bowel Disease 2008 ·Journal of Immunotoxicology ·Gail L. Matters,John F. Harms,Christopher O. McGovern,Leo R. Fitzpatrick,(unknown),(unknown),Jill P. Smith	23
9	Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia 2008 ·Journal of Pharmacology and Experimental Therapeutics ·C J Schmidt,Douglas S. Chapin,(unknown),Michael L. Corman,Mihály Hajós,John F. Harms,William E. Hoffman,Lorraine A. Lebel,Sheryl A. McCarthy,(unknown),(unknown),Mark J. Majchrzak,Andres D. Ramirez,Karl T. Schmidt,P A Seymour,Judith A. Siuciak,F. David Tingley,Robert D. Williams,Patrick R. Verhoest,Frank S. Menniti	238
10	Behavioral characterization of mice deficient in the phosphodiesterase-10A (PDE10A) enzyme on a C57/Bl6N congenic background 2007 ·Neuropharmacology ·Judith A. Siuciak,Sheryl A. McCarthy,Douglas S. Chapin,A. Martin,John F. Harms,Christopher J. Schmidt	49
11	A novel, non-substrate-based series of glycine type 1 transporter inhibitors derived from high-throughput screening 2007 ·Bioorganic & Medicinal Chemistry Letters ·John Lowe,Susan E. Drozda,(unknown),Mark Peakman,(unknown),John P. Gibbs,John F. Harms,Christopher Schmidt,Katherine Fisher,Christine A. Strick,Anne W. Schmidt,(unknown),Lorraine A. Lebel	7
12	Inhibition of the striatum-enriched phosphodiesterase PDE10A: A novel approach to the treatment of psychosis 2006 ·Neuropharmacology ·Judith A. Siuciak,Douglas S. Chapin,John F. Harms,Lorraine A. Lebel,Sheryl A. McCarthy,Leslie K. Chambers,Alka Shrikhande,Stephen K.-F. Wong,Frank S. Menniti,Christopher J. Schmidt	226
13	MDA-MB-435 human breast carcinoma metastasis to bone 2003 ·Clinical & Experimental Metastasis ·John F. Harms,(unknown)	52
14	KISS1 metastasis suppression and emergent pathways 2003 ·Clinical & Experimental Metastasis ·John F. Harms,Danny R. Welch,Mary E. Miele	88
15	Maintaining GFP Tissue Fluorescence through Bone Decalcification and Long-Term Storage 2002 ·BioTechniques ·John F. Harms,Lynn R. Budgeon,Neil D. Christensen,Danny R. Welch	21
16	Analysis of mechanisms underlying BRMS1 suppression of metastasis 2000 ·Clinical & Experimental Metastasis ·Rajeev S. Samant,M. Jabed Seraj,Margaret Saunders,Toshiyuki Sakamaki,Lalita A. Shevde,John F. Harms,(unknown),Steven F. Goldberg,Lynn R. Budgeon,William J. Meehan,(unknown),Neil D. Christensen,Michael F. Verderame,Henry J. Donahue,Danny R. Welch	94
17	Metastasis-suppressed C8161 melanoma cells arrest in lung but fail to proliferate 1999 ·Clinical & Experimental Metastasis ·Steven F. Goldberg,John F. Harms,Kim Quon,Danny R. Welch	71
18	A use-dependent sodium channel antagonist, 619C89, in reduction of ischemic brain damage and glutamate release after acute subdural hematoma in the rat 1996 ·Journal of neurosurgery ·(unknown),John F. Harms,(unknown),Ross Bullock	26
19	Potentiation of N‐Methyl‐d‐Aspartate‐Stimulated Dopamine Release from Rat Brain Slices by Aluminum Fluoride and Carbachol 1992 ·Journal of Neurochemistry ·John J. Woodward,John F. Harms	11
20	The putative polyamine antagonists ifenprodil and SL 82.0715 enhance dopamine efflux from rat striatal slices independent of NMDA receptor activation 1992 ·European Journal of Pharmacology ·John J. Woodward,John F. Harms	13

About John F. Harms

John F. Harms is a scholar working on Cellular and Molecular Neuroscience, Pharmacology and Molecular Biology, having authored 32 papers that have together received 1.6k indexed citations. Recurring topics across this work include Phosphodiesterase function and regulation (10 papers), Receptor Mechanisms and Signaling (8 papers) and Cholinesterase and Neurodegenerative Diseases (6 papers). The work is most often cited by research in Pharmacology (450 citations), Molecular Biology (1.2k citations) and Cellular and Molecular Neuroscience (267 citations). John F. Harms has collaborated with scholars based in United States, Netherlands and India. Frequent co-authors include Danny R. Welch, Christopher J. Schmidt, Douglas S. Chapin, Frank S. Menniti, Sheryl A. McCarthy, Judith A. Siuciak, Lorraine A. Lebel, Mary E. Miele, Steven F. Goldberg and Patrick R. Verhoest. Their work appears in journals such as Journal of Neuroscience, Biochemistry and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact